Malignant Peritoneal Neoplasm

Observed

→ investigated in trials for

Carboplatinsmall molecule

71 trials (21 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal_antibody

53 trials (21 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

26 trials (12 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cisplatinsmall molecule

24 trials (6 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Gemcitabinesmall molecule

24 trials (10 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Topotecansmall molecule

24 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

23 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Doxorubicinsmall molecule

23 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Olaparibsmall_molecule

21 trials (14 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Niraparibsmall_molecule

12 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Docetaxelsmall molecule

10 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pemetrexedsmall molecule

10 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

9 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Mirvetuximab Soravtansineadc

8 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

Primary Peritoneal Carcinoma

Malignant Peritoneal Neoplasm studied in …STUDIED_INderived10 of 502show all (up to 200)
→ studied in	NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · condition mapped CURATED_BROADER · 502 trials mapped (133 active)	—	—	Primary Peritoneal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 502 trials mapped (133 active)	—	—	Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06057935Phase 2 · recruiting A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma · condition mapped ALIAS · 502 trials mapped (133 active)	—	—	Peritoneal Malignant Mesothelioma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07776691Phase 3 · recruiting A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) · condition mapped ALIAS · 502 trials mapped (133 active)	—	—	Malignant Peritoneal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07708753Phase 3 · recruiting A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers · condition mapped ALIAS · 502 trials mapped (133 active)	—	—	Platinum-Resistant Primary Peritoneal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05001880Phase 2 · recruiting Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma · condition mapped ONTOLOGY_EXACT · 502 trials mapped (133 active)	—	—	Peritoneal Malignant Mesothelioma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05276973Phase 1 · active not recruiting Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 502 trials mapped (133 active)	—	—	Primary Peritoneal Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05446298Phase 2 · active not recruiting ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 502 trials mapped (133 active)	—	—	Primary Peritoneal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06714617Phase 1 · terminated Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 502 trials mapped (133 active)	—	—	Malignant Peritoneal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 502 trials mapped (133 active)	—	—	Primary Peritoneal Carcinosarcoma	1	Observed	clinicaltrials	graph →

Malignant Peritoneal Neoplasm studied in …STUDIED_INderived10 of 502show all (up to 200)

→ studied in

NCT05564377Phase 2 · recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · condition mapped CURATED_BROADER · 502 trials mapped (133 active)

—

Observed

Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma

→ studied in

NCT07504588Phase 2 · recruiting

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 502 trials mapped (133 active)

—

Observed

Peritoneal Malignant Mesothelioma

→ studied in

NCT06057935Phase 2 · recruiting

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma · condition mapped ALIAS · 502 trials mapped (133 active)

—

Observed

→ studied in

NCT07776691Phase 3 · recruiting

A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) · condition mapped ALIAS · 502 trials mapped (133 active)

—

Observed

Platinum-Resistant Primary Peritoneal Carcinoma

→ studied in

NCT07708753Phase 3 · recruiting

A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers · condition mapped ALIAS · 502 trials mapped (133 active)

—

Observed

Peritoneal Malignant Mesothelioma

→ studied in

NCT05001880Phase 2 · recruiting

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma · condition mapped ONTOLOGY_EXACT · 502 trials mapped (133 active)

—

Observed

Primary Peritoneal Endometrioid Adenocarcinoma

→ studied in

NCT05276973Phase 1 · active not recruiting

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 502 trials mapped (133 active)

—

Observed

Primary Peritoneal Carcinoma

→ studied in

NCT05446298Phase 2 · active not recruiting

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 502 trials mapped (133 active)

—

Observed

→ studied in

NCT06714617Phase 1 · terminated

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 502 trials mapped (133 active)

—

Observed

Primary Peritoneal Carcinosarcoma

→ studied in

NCT05920798Phase 1/Phase 2 · active not recruiting

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 502 trials mapped (133 active)

—

Observed